GRAND PHARMA Surges Over 6% in Afternoon Trading as Myopia Drug GPN00884 Initiates China Phase IIa Trial

Deep News11-03

GRAND PHARMA (00512) rose 6.42% in afternoon trading, reaching HK$8.79 with a turnover of HK$102 million.

The company recently announced that its global innovative ophthalmic drug GPN00884, designed to slow myopia progression in children, has completed the first patient enrollment and dosing in its China Phase IIa clinical study. This milestone marks GPN00884's entry into a critical phase exploring dosage and preliminary efficacy. If successful, the drug could introduce a novel solution for managing childhood myopia progression.

Notably, in July this year, GRAND PHARMA launched varenicline tartrate nasal spray (OC-01) in mainland China, revolutionizing dry eye treatment with its nasal administration approach. Recently, the company held a national launch event for OC-01 during the "11th Global Dry Eye Academic Conference," themed "Caring for Dry Eye Patients, Ushering in the Era of Natural Tears—2025 Advances in Dry Eye Diagnosis & Treatment and Ocular Surface Health Ecosystem." The event highlighted OC-01's shift from traditional "external replacement" therapies to an "innate activation" approach in dry eye management.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1172088409?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-03 13:10","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172088409","market":"sh","top_or_hot":-1,"title":"GRAND PHARMA Surges Over 6% in Afternoon Trading as Myopia Drug GPN00884 Initiates China Phase IIa Trial","media":"Deep News","content":"<p>GRAND PHARMA (00512) rose 6.42% in afternoon trading, reaching HK$8.79 with a turnover of HK$102 million.</p>\n<p>The company recently announced that its global innovative ophthalmic drug GPN00884, designed to slow myopia progression in children, has completed the first patient enrollment and dosing in its China Phase IIa clinical study. This milestone marks GPN00884's entry into a critical phase exploring dosage and preliminary efficacy. If successful, the drug could introduce a novel solution for managing childhood myopia progression.</p>\n<p>Notably, in July this year, GRAND PHARMA launched varenicline tartrate nasal spray (OC-01) in mainland China, revolutionizing dry eye treatment with its nasal administration approach. Recently, the company held a national launch event for OC-01 during the \"11th Global Dry Eye Academic Conference,\" themed \"Caring for Dry Eye Patients, Ushering in the Era of Natural Tears—2025 Advances in Dry Eye Diagnosis & Treatment and Ocular Surface Health Ecosystem.\" The event highlighted OC-01's shift from traditional \"external replacement\" therapies to an \"innate activation\" approach in dry eye management.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GRAND PHARMA Surges Over 6% in Afternoon Trading as Myopia Drug GPN00884 Initiates China Phase IIa Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGRAND PHARMA Surges Over 6% in Afternoon Trading as Myopia Drug GPN00884 Initiates China Phase IIa Trial\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2025-11-03 13:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GRAND PHARMA (00512) rose 6.42% in afternoon trading, reaching HK$8.79 with a turnover of HK$102 million.</p>\n<p>The company recently announced that its global innovative ophthalmic drug GPN00884, designed to slow myopia progression in children, has completed the first patient enrollment and dosing in its China Phase IIa clinical study. This milestone marks GPN00884's entry into a critical phase exploring dosage and preliminary efficacy. If successful, the drug could introduce a novel solution for managing childhood myopia progression.</p>\n<p>Notably, in July this year, GRAND PHARMA launched varenicline tartrate nasal spray (OC-01) in mainland China, revolutionizing dry eye treatment with its nasal administration approach. Recently, the company held a national launch event for OC-01 during the \"11th Global Dry Eye Academic Conference,\" themed \"Caring for Dry Eye Patients, Ushering in the Era of Natural Tears—2025 Advances in Dry Eye Diagnosis & Treatment and Ocular Surface Health Ecosystem.\" The event highlighted OC-01's shift from traditional \"external replacement\" therapies to an \"innate activation\" approach in dry eye management.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"00512","symbol_name":"远大医药","start_time":0,"source_url":"","article_id":"1172088409","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172088409","pubTimestamp":1762146659,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"GRAND PHARMA (00512) rose 6.42% in afternoon trading, reaching HK$8.79 with a turnover of HK$102 million. The company recently announced that its global innovative ophthalmic drug GPN00884, designed...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"00512":"远大医药","BK1191":"制药"},"translate_title":"近视药物GPN00884启动中国IIa期试验远大医药午盘大涨超6%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"00512":1},"content_text":"GRAND PHARMA (00512) rose 6.42% in afternoon trading, reaching HK$8.79 with a turnover of HK$102 million.\nThe company recently announced that its global innovative ophthalmic drug GPN00884, designed to slow myopia progression in children, has completed the first patient enrollment and dosing in its China Phase IIa clinical study. This milestone marks GPN00884's entry into a critical phase exploring dosage and preliminary efficacy. If successful, the drug could introduce a novel solution for managing childhood myopia progression.\nNotably, in July this year, GRAND PHARMA launched varenicline tartrate nasal spray (OC-01) in mainland China, revolutionizing dry eye treatment with its nasal administration approach. Recently, the company held a national launch event for OC-01 during the \"11th Global Dry Eye Academic Conference,\" themed \"Caring for Dry Eye Patients, Ushering in the Era of Natural Tears—2025 Advances in Dry Eye Diagnosis & Treatment and Ocular Surface Health Ecosystem.\" The event highlighted OC-01's shift from traditional \"external replacement\" therapies to an \"innate activation\" approach in dry eye management.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1172088409","isCrawlerRequest":true}